Abivax Shares Surge 9.87% Contrary to a Declining CAC 40

Impressive Recovery for Abivax Shares

Abivax stock displayed a spectacular increase this Thursday, surpassing its 20-day moving average (103.38 euros) and its 50-day moving average (102.83 euros), levels it had previously fallen below in recent sessions. This simultaneous crossing signals a short-term reversal, following a challenging quarter with a decline of 8.64% over three months. The RSI, which was at 32, indicated a pronounced oversold zone: thus, today's rebound follows a logical technical correction after a bearish excess. The monthly volatility, measured at 13.54, remains high for a stock of this capitalization, reflecting the fluctuations typical of the biotech sector. The stock is now trading above the support identified at 93.70 euros and is approaching the resistance at 112.40 euros. Over the past year, the performance remains exceptional, with a gain of 1,690%, illustrating the unique trajectory of the stock since spring 2025.

Significant Uptrend Ahead of Annual Financial Report

This Thursday's bullish acceleration takes on special significance eleven days before the presentation of the 2025 annual accounts of Abivax, scheduled for March 23. This financial event is a major occasion for the company, which specializes in the development of treatments for chronic inflammatory diseases. The published data will allow for an assessment of the biotech's spending trajectory and the state of its cash reserves, two crucial parameters for a company in an advanced clinical phase. The financial calendar then schedules the communication of the first quarter 2026 results on June 1, followed by the half-year accounts on September 14. In a cautious market context—the CAC 40 is down during the session while the Nikkei 225 closed down 1.04% this Thursday and the Hang Seng dropped 0.70% at the day's close—the dynamics specific to Abivax's stock distinctly stands out from the general trends observed in European and Asian markets on March 12.